Deutsch English Français

Contact

EP2863910

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2863910

EP2863910 - COMPOSITIONS AND METHODS FOR REGULATING GLUCOSE HOMEOSTASIS AND INSULIN ACTION [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 15.01.2021 Database last updated on 12.07.2024
Former	The patent has been granted Status updated on 07.02.2020
Former	Grant of patent is intended Status updated on 26.09.2019
Former	Examination is in progress Status updated on 01.09.2017
Most recent event Tooltip	08.07.2022	Lapse of the patent in a contracting state New state(s): MK	published on 10.08.2022 [2022/32]
Applicant(s)	For all designated states University of Virginia Patent Foundation 250 West Main Street, Suite 300 Charlottesville, VA 22902 / US
	[2015/18]
Inventor(s)	01 / HOEHN, Kyle 975 Pintail Lane Charlottesville, VA 22903 / US
	02 / KENWOOD, Brandon 1821 Jefferson Park Avenue Apt. 13 Charlottesville, VA 22903 / US
	[2019/43]
Former [2015/18]	01 / HOEHN, Kyle 975 Pintail Lane Charlottesville, VA 22903 / US
	02 / KENWOOD, Brandon 1821 Jefferson Park Avenue Apt. 13 Charolottesville, VA 22903 / US
Representative(s)	Murgitroyd & Company 165-169 Scotland Street Glasgow G5 8PL / GB
	[N/P]
Former [2020/11]	Murgitroyd & Company Murgitroyd House 165-169 Scotland Street Glasgow G5 8PL / GB
Former [2015/18]	Main, Malcolm Charles Murgitroyd & Company Scotland House 165-169 Scotland Street Glasgow G5 8PL / GB
Application number, filing date	13807833.2	20.06.2013
	[2020/11]
	WO2013US46740
Priority number, date	US201261662268P	20.06.2012 Original published format: US 201261662268 P
	[2015/18]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2013192388
	Date:	27.12.2013
	Language:	EN
	[2013/52]
	Type:	A1 Application with search report
	No.:	EP2863910
	Date:	29.04.2015
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 27.12.2013 takes the place of the publication of the European patent application.
	[2015/18]
	Type:	B1 Patent specification
	No.:	EP2863910
	Date:	11.03.2020
	Language:	EN
	[2020/11]
Search report(s)	International search report - published on:	US	27.12.2013
	(Supplementary) European search report - dispatched on:	EP	16.06.2016
Classification	IPC:	A61K31/4985, C07D498/04, G01N33/50, A61P3/10, A61P25/28, A61P3/06, A61P9/04, A61P9/10, A61P3/04, A61P43/00	[2019/41]
	CPC:	C07D498/04 (EP,US); A61K31/4985 (EP,US); A61K9/0053 (US); A61P25/28 (EP); A61P3/04 (EP); A61P3/06 (EP); (+) A61P3/10 (EP); A61P43/00 (EP); A61P9/04 (EP); A61P9/10 (EP); G01N33/5014 (US); G01N33/5079 (US); G01N2500/10 (US) (-)
	Former IPC [2016/13]	A61K31/4985, C07D498/04, G01N33/50
	Former IPC [2015/18]	A61K31/495, C07D498/04
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/18]
Extension states	BA	Not yet paid
	ME	Not yet paid
Title	German:	ZUSAMMENSETZUNGEN UND VERFAHREN ZUR REGULIERUNG EINER GLUCOSEHOMÖOSTASE UND EINER INSULINWIRKUNG	[2015/18]
	English:	COMPOSITIONS AND METHODS FOR REGULATING GLUCOSE HOMEOSTASIS AND INSULIN ACTION	[2015/18]
	French:	COMPOSITIONS ET PROCÉDÉS POUR RÉGULER L'HOMÉOSTASIE DU GLUCOSE ET L'ACTION DE L'INSULINE	[2015/18]
Entry into regional phase	19.01.2015	National basic fee paid
	19.01.2015	Search fee paid
	19.01.2015	Designation fee(s) paid
	19.01.2015	Examination fee paid
Examination procedure	19.01.2015	Examination requested [2015/18]
	16.01.2017	Amendment by applicant (claims and/or description)
	04.09.2017	Despatch of a communication from the examining division (Time limit: M06)
	16.04.2018	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	21.06.2018	Reply to a communication from the examining division
	26.10.2018	Despatch of a communication from the examining division (Time limit: M06)
	06.05.2019	Reply to a communication from the examining division
	27.09.2019	Communication of intention to grant the patent
	27.01.2020	Fee for grant paid
	27.01.2020	Fee for publishing/printing paid
	27.01.2020	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 04.09.2017
Opposition(s)	14.12.2020	No opposition filed within time limit [2021/07]
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	21.06.2018	Request for further processing filed
	21.06.2018	Full payment received (date of receipt of payment) Request granted
	03.07.2018	Decision despatched
Fees paid	Renewal fee
	29.06.2015	Renewal fee patent year 03
	27.06.2016	Renewal fee patent year 04
	27.06.2017	Renewal fee patent year 05
	27.06.2018	Renewal fee patent year 06
	27.06.2019	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	20.06.2013
	AL	11.03.2020
	AT	11.03.2020
	CY	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	MC	11.03.2020
	MK	11.03.2020
	MT	11.03.2020
	NL	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	TR	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IE	20.06.2020
	LU	20.06.2020
	BE	30.06.2020
	CH	30.06.2020
	LI	30.06.2020
	IS	11.07.2020
	PT	05.08.2020
	[2022/31]
Former [2022/30]	HU	20.06.2013
	AL	11.03.2020
	AT	11.03.2020
	CY	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	MC	11.03.2020
	MT	11.03.2020
	NL	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	TR	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IE	20.06.2020
	LU	20.06.2020
	BE	30.06.2020
	CH	30.06.2020
	LI	30.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2022/27]	HU	20.06.2013
	AT	11.03.2020
	CY	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	MC	11.03.2020
	MT	11.03.2020
	NL	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	TR	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IE	20.06.2020
	LU	20.06.2020
	BE	30.06.2020
	CH	30.06.2020
	LI	30.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2022/26]	AT	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	MC	11.03.2020
	NL	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	TR	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IE	20.06.2020
	LU	20.06.2020
	BE	30.06.2020
	CH	30.06.2020
	LI	30.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2021/24]	AT	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	MC	11.03.2020
	NL	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IE	20.06.2020
	LU	20.06.2020
	BE	30.06.2020
	CH	30.06.2020
	LI	30.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2021/20]	AT	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	MC	11.03.2020
	NL	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IE	20.06.2020
	LU	20.06.2020
	CH	30.06.2020
	LI	30.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2021/15]	AT	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	MC	11.03.2020
	NL	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	LU	20.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2021/11]	AT	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	MC	11.03.2020
	NL	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2021/08]	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	NL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2020/50]	CZ	11.03.2020
	EE	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	NL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2020/49]	CZ	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	NL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2020/48]	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	NL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2020/47]	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	NL	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
Former [2020/46]	FI	11.03.2020
	HR	11.03.2020
	LV	11.03.2020
	NL	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
Former [2020/45]	FI	11.03.2020
	HR	11.03.2020
	LV	11.03.2020
	NL	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
Former [2020/39]	FI	11.03.2020
	HR	11.03.2020
	LV	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
Former [2020/38]	FI	11.03.2020
	HR	11.03.2020
	LV	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	NO	11.06.2020
	GR	12.06.2020
Former [2020/37]	FI	11.03.2020
	HR	11.03.2020
	LV	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	NO	11.06.2020
Former [2020/35]	FI	11.03.2020
	NO	11.06.2020
Documents cited:	Search	[I]WO2005044270 (4SC AG [DE], et al) [I] 1-13 * page 27, line 24 - page 28, line 24 ** claims 1-5 *;
		[X]WO2006044402 (COMPASS PHARMACEUTICALS LLC [US], et al) [X] 1-6,8-13 * claims 34-39 * * compounds CP5019460, CP3306869 * * page 28, paragraphs 3-4 *;
		[X]WO2007005403 (SCHERING CORP [US], et al) [X] 1-6,8-13 * claims 1, 61-63; examples 11a, 12a, 18a, 19a, 23a, 30a, 37a, 42a *;
		[X] - I B Starchenkov ET AL, "CHEMISTRY OF FURAZANO[3,4-b]PYRAZINES 3.* METHOD FOR THE SYNTHESIS OF 5,6-DISUBST1TUTED FURAZANO[3,4-b] PYRAZINES", Chemistry of Heterocyclic Compounds, (19970101), URL: http://download.springer.com/static/pdf/456/art%3A10.1007%2FBF02290874.pdf?originUrl=http://link.springer.com/article/10.1007/BF02290874&token2=exp=1456237335~acl=/static/pdf/456/art%253A10.1007%252FBF02290874.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2FBF02290874~hmac=cae629, XP055252568 [X] 1-4,12 LXXVI (table 2) *
	International search	[Y]US2002127536 (APRILLE JUNE R [US]);
		[Y]WO2005044270 (4SC AG [DE], et al);
		[Y]US7005274 (TERKELTAUB ROBERT [US], et al);
		[X]WO2007005403 (SCHERING CORP [US], et al);
		[Y]WO2010048114 (METAPROTEOMICS LLC [US], et al);
		[X]US2010222356 (BAURES PAUL W [US], et al);
		[Y]US2011178077 (BRODIN PRISCILLE [FR], et al);
		[Y]WO2012052068 (UNIV COLLEGE CORK NAT UNIV IE [IE], et al)
	by applicant	US4394320
		US4472840
		US4559157
		US4608392
		US4820508
		US4938949
		US4992478
		US5366509
		US5606019
		US5645591
		US5683459
		WO2005044270
		WO2007005403
		- ONG SE; SCHENONE M; MARGOLIN AA; LI X; DO K; DOUD MK et al., "Identifying the proteins to which small-molecule probes and drugs bind in cells", Proc Natl Acad Sci USA, (20090000), vol. 106, no. 12, pages 4617 - 22
		- TSENG YH; CYPESS AM; KAHN CR, "Cellular bioenergetics as a target for obesity therapy", Nat Rev Drug Discov., (20100000), vol. 9, no. 6, pages 465 - 82
		- BRUNMAIR B; STANIEK K; GRAS F; SCHARF N; ALTHAYM A; CLARA R et al., "Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?", Diabetes, (20040000), vol. 53, no. 4, pages 1052 - 9
		- HOEHN KL; SALMON AB; HOHNEN-BEHRENS C; TURNER N; HOY AJ; MAGHZAL GJ et al., "Insulin resistance is a cellular antioxidant defense mechanism", Proc Natl Acad Sci USA, (20090000), vol. 106, no. 42, pages 17787 - 92
		- HOEHN KL; HOHNEN-BEHRENS C; CEDERBERG A; WU LE; TURNER N; YUASA T et al., "IRS 1-independent defects define major nodes of insulin resistance", Cell Metab., (20080000), vol. 7, no. 5, pages 421 - 33
		- YIP MF; RAMM G; LARANCE M; HOEHN KL; WAGNER MC; GUILHAUS M et al., "CaMKII-mediated phosphorylation of the myosin motor Myolc is required for insulin-stimulated GLUT4 translocation in adipocytes", Cell Metab., (20080000), vol. 8, no. 5, pages 384 - 98
		- HOEHN KL; TURNER N; SWARBRICK MM; WILKS D; PRESTON E; PHUA Y et al., "Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity", Cell Metab., (20100000), vol. 1 1, no. 1, pages 70 - 6
		- LARANCE M; ROWLAND AF; HOEHN KL; HUMPHREYS DT; PREISS T; GUILHAUS M et al., "Global phosphoproteomics identifies a major role for AKT and 14-3-3 in regulating EDC3", Mol Cell Proteomics, (20100000), vol. 9, no. 4, pages 682 - 94
		- DEL PRATO S, "Megatrials in type 2 diabetes. From excitement to frustration?", Diabetologia, (20090000), vol. 52, no. 7, pages 1219 - 26, XP019698625
		- STOCKTON MTAA, "Dinitrophenol in the treatment of obesity: Final report", JAMA, (19350000), vol. 5, no. 105, pages 332 - 7
		- COLMAN E, "Dinitrophenol and obesity: an early twentieth-century regulatory dilemma", Regul Toxicol Pharmacol., (20070000), vol. 48, no. 2, doi:doi:10.1016/j.yrtph.2007.03.006, pages 115 - 7, XP022102807 DOI: http://dx.doi.org/10.1016/j.yrtph.2007.03.006
		- CALDEIRA DA SILVA CC; CERQUEIRA FM; BARBOSA LF; MEDEIROS MH; KOWALTOWSKI AJ, "Mild mitochondrial uncoupling in mice affects energy metabolism, redox balance and longevity", Aging Cell, (20080000), vol. 7, no. 4, doi:doi:10.1111/j.1474-9726.2008.00407.x, pages 552 - 60, XP055257324 DOI: http://dx.doi.org/10.1111/j.1474-9726.2008.00407.x
		- LOU PH; HANSEN BS; OLSEN PH; TULLIN S; MURPHY MP; BRAND MD, "Mitochondrial uncouplers with an extraordinary dynamic range", Biochem J., (20070000), vol. 407, no. 1, doi:doi:10.1042/BJ20070606, pages 129 - 40, XP055518173 DOI: http://dx.doi.org/10.1042/BJ20070606
		- HEYTLER PG; PRICHARD WW, "A new class of uncoupling agents--carbonyl cyanide phenylhydrazones", Biochem Biophys Res Commun., (19620000), vol. 7, doi:doi:10.1016/0006-291X(62)90189-4, pages 272 - 5, XP024832090 DOI: http://dx.doi.org/10.1016/0006-291X(62)90189-4
		- TURRENS JF, "Superoxide production by the mitochondrial respiratory chain", Bioscience reports, (19970000), vol. 17, no. 1, pages 3 - 8, XP019274326
		- BRAND MD; ESTEVES TC, "Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3", Cell Metab., (20050000), vol. 2, no. 2, pages 85 - 93
		- MAILLOUX RJ; HARPER ME, "Mitochondrial proticity and ROS signaling: lessons from the uncoupling proteins", Trends Endocrinol Metab., (20120000), vol. 23, no. 9, pages 451 - 8
		- PARK D; HAN CZ; ELLIOTT MR; KINCHEN JM; TRAMPONT PC; DAS S; COLLINS S; LYSIAK JJ; HOEHN KL; RAVICHANDRAN KS, "Continued clearance of apoptotic cells critically depends on the phagocyte Ucp2 protein", Nature, (20110000), vol. 477, no. 7363, pages 220 - 4
		- WU YN; MUNHALL AC; JOHNSON SW, "Mitochondrial uncoupling agents antagonize rotenone actions in rat substantia nigra dopamine neurons", Brain Res., (20110000), vol. 1395, doi:doi:10.1016/j.brainres.2011.04.032, pages 86 - 93, XP028385909 DOI: http://dx.doi.org/10.1016/j.brainres.2011.04.032
		- PANDYA JD; PAULY JR; SULLIVAN PG, "The optimal dosage and window of opportunity to maintain mitochondrial homeostasis following traumatic brain injury using the uncoupler FCCP", Exp Neurol., (20090000), vol. 218, no. 2, doi:doi:10.1016/j.expneurol.2009.05.023, pages 381 - 9, XP026321636 DOI: http://dx.doi.org/10.1016/j.expneurol.2009.05.023
		- KORDE AS; PETTIGREW LC; CRADDOCK SD; MARAGOS WF, "The mitochondrial uncoupler 2,4-dinitrophenol attenuates tissue damage and improves mitochondrial homeostasis following transient focal cerebral ischemia", J Neurochem., (20050000), vol. 94, no. 6, doi:doi:10.1111/j.1471-4159.2005.03328.x, pages 1676 - 84, XP055257318 DOI: http://dx.doi.org/10.1111/j.1471-4159.2005.03328.x
		- MODRIANSKY M; GABRIELOVA E, "Uncouple my heart: the benefits of inefficiency", J Bioenerg Biomembr., (20090000), vol. 41, no. 2, pages 133 - 6, XP019680372
		- BRENNAN JP; SOUTHWORTH R; MEDINA RA; DAVIDSON SM; DUCHEN MR; SHATTOCK MJ, "Mitochondrial uncoupling, with low concentration FCCP, induces ROS-dependent cardioprotection independent of KATP channel activation", Cardiovasc Res., (20060000), vol. 72, no. 2, doi:doi:10.1016/j.cardiores.2006.07.019, pages 313 - 21, XP025011202 DOI: http://dx.doi.org/10.1016/j.cardiores.2006.07.019
		- MURPHY MP; SMITH RAJ, "Targeting Antioxidants to Mitochondria by Conjugation to Lipophilic Cations", Annual Review of Pharmacology and Toxicology, (20070000), vol. 47, no. l, pages 629 - 56
		- MARRACHE S; DHAR S, "Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics", Proceedings of the National Academy of Sciences, (20120000), vol. 109, no. 40, doi:doi:10.1073/pnas.1210096109, pages 16288 - 93, XP055212398 DOI: http://dx.doi.org/10.1073/pnas.1210096109
		- SMITH RA; HARTLEY RC; MURPHY MP, "Mitochondria-Targeted Small Molecule Therapeutics and Probes", Antioxidants & Redox Signaling, (20110000), vol. 15, pages 3021 - 38
		- BLAIKIE FH; BROWN SE; SAMUELSSON LM; BRAND MD; SMITH RA; MURPHY MP, "Targeting dinitrophenol to mitochondria: limitations to the development of a self-limiting mitochondrial protonophore", Bioscience Reports, (20060000), vol. 26, no. 3, doi:doi:10.1007/s10540-006-9018-8, pages 231 - 43, XP019391966 DOI: http://dx.doi.org/10.1007/s10540-006-9018-8
		- SMITH RA; MURPHY MP, "Animal and human studies with the mitochondria-targeted antioxidant MitoQ", Annals of the New York Academy of Sciences, (20100000), vol. 1201, pages 96 - 103
		- RODRIGUEZ-CUENCA S; COCHEME HM; LOGAN A; ABAKUMOVA I; PRIME TA; ROSE C; VIDAL-PUIG A; SMITH AC; RUBINSZTEIN DC; FEARNLEY IM, "Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice", Free Radical Biology and Medicine, (20100000), vol. 48, no. 1, pages 161 - 72, XP026813339
		- HORTON KL; STEWART KM; FONSECA SB; GUO Q; KELLEY SO, "Mitochondria-Penetrating Peptides", Chemistry and Biology, (20080000), vol. 15, no. 4, doi:doi:10.1016/j.chembiol.2008.03.015, pages 375 - 82, XP022613220 DOI: http://dx.doi.org/10.1016/j.chembiol.2008.03.015
		- ZHAO K; ZHAO G-M; WU D; SOONG Y; BIRK AV; SCHILLER PW; SZETO HH, "Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury", Journal of Biological Chemistry, (20040000), vol. 279, no. 33, doi:doi:10.1074/JBC.M402999200, pages 34682 - 90, XP002594478 DOI: http://dx.doi.org/10.1074/JBC.M402999200
		- BRYSON DI; ZHANG W; RAY WK; SANTOS WL, "Screening of a Branched Peptide Library with HIV-1 TAR RNA", Mol BioSyst., (20090000), vol. 5, pages 1070 - 3
		- BRYSON DI; ZHANG W; MCLENDON PM; REINEKE TM; SANTOS WL, "Toward targeting RNA structure: branched peptides as cell-permeable ligands to TAR RNA", ACS Chemical Biology, (20120000), vol. 7, no. l, pages 210 - 7
		- HOEHN KL; HOHNEN-BEHRENS C; CEDERBERG A; WU LE; TURNER N; YUASA T; EBINA Y; JAMES DE, "IRS l-independent defects define major nodes of insulin resistance", Cell Metab., (20080000), vol. 7, no. 5, pages 421 - 33
		- HOEHN KL; SALMON AB; HOHNEN-BEHRENS C; TURNER N; HOY AJ; MAGHZAL GJ; STOCKER R; VAN REMMEN H; KRAEGEN EW; COONEY GJ, "Insulin resistance is a cellular antioxidant defense mechanism", Proc Natl Acad Sci USA, (20090000), vol. 106, no. 42, pages 17787 - 92
		- HOEHN KL; TURNER N; SWARBRICK MM; WILKS D; PRESTON E; PHUA Y; JOSHI H; FURLER SM; LARANCE M; HEGARTY BD, "Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity", Cell Metab., (20100000), vol. 11, no. 1, pages 70 - 6
		- MACARTHUR DG; SETO JT; CHAN S; QUINLAN KG; RAFTERY JM; TURNER N; NICHOLSON MD; KEE AJ; HARDEMAN EC; GUNNING PW, "An Actn3 knockout mouse provides mechanistic insights into the association between alpha-actinin-3 deficiency and human athletic performance", Hum Mol Genet., (20080000), vol. 17, no. 8, pages 1076 - 86
		- BONNARD C; DURAND A; PEYROL S; CHANSEAUME E; CHAUVIN MA; MORIO B; VIDAL H; RIEUSSET J, "Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice", J Clin Invest., (20080000), vol. 118, no. 2, pages 789 - 800
		- SAUERBECK A; PANDYA J; SINGH I; BITTMAN K; READNOWER R; BING G; SULLIVAN P, "Analysis of regional brain mitochondrial bioenergetics and susceptibility to mitochondrial inhibition utilizing a microplate based system", J Neurosci Methods, (20110000), vol. 198, no. 1, doi:doi:10.1016/j.jneumeth.2011.03.007, pages 36 - 43, XP028383803 DOI: http://dx.doi.org/10.1016/j.jneumeth.2011.03.007
		- DJOUADI F; RIVEAU B; MERLET-BENICHOU C; BASTIN J, "Tissue-specific regulation of medium-chain acyl-CoA dehydrogenase gene by thyroid hormones in the developing rat", Biochem J., (19970000), vol. 324, pages 289 - 94
		- BRUCE CR; THRUSH AB; MERTZ VA; BEZAIRE V; CHABOWSKI A; HEIGENHAUSER GJ; DYCK DJ, "Endurance training in obese humans improves glucose tolerance and mitochondrial fatty acid oxidation and alters muscle lipid content", Am J Physiol Endocrinol Metab., (20060000), vol. 291, no. 1, pages E99 - E107
		- TURNER N; BRUCE CR; BEALE SM; HOEHN KL; SO T; ROLPH MS; COONEY GJ, "Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents", Diabetes, (20070000), vol. 56, no. 8, pages 2085 - 92
		- KIM JY; HICKNER RC; CORTRIGHT RL; DOHM GL; HOUMARD JA, "Lipid oxidation is reduced in obese human skeletal muscle", Am J Physiol Endocrinol Metab., (20000000), vol. 279, no. 5, pages 1039 - 44
		- LIN L; SAHA PK; MA X; HENSHAW 10; SHAO L; CHANG BH; BURAS ED; TONG Q; CHAN L; MCGUINNESS OP, "Ablation of ghrelin receptor reduces adiposity and improves insulin sensitivity during aging by regulating fat metabolism in white and brown adipose tissues", Aging Cell, (20110000), vol. 10, no. 6, pages 996 - 1010
		- S. S. KORSHUNOV; V. P. SKULACHEV; A. A. STARKOV, FEBS Lett, (19971013), vol. 416, page 15
		- J. F. TURRENS, Biosci Rep, (19970200), vol. 17, page 3
		- C. L. QUINLAN et al., J Biol Chem, (20120803), vol. 287, page 27255
		- M. N. SACK, Cardiovasc Res, (20061101), vol. 72, page 210
		- C. J. MCLEOD; A. AZIZ; R. F. HOYT, JR.; J. P. MCCOY, JR.; M. N. SACK, J Biol Chem, (20050930), vol. 280, page 33470
		- A. S. KORDE; L. C. PETTIGREW; S. D. CRADDOCK; W. F. MARAGOS, J Neurochem, (20050900), vol. 94, page 1676
		- M. MODRIANSKY; E. GABRIELOVA, J Bioenerg Biomembr, (20090400), vol. 41, page 133
	- Y. N. WU; A. C. MUNHALL; S. W. JOHNSON, Brain Res, (20110613), vol. 1395, page 86
	- K. L. HOEHN et al., Proc Natl Acad Sci U S A, (20091020), vol. 106, page 17787
	- C. C. CALDEIRA DA SILVA; F. M. CERQUEIRA; L. F. BARBOSA; M. H. MEDEIROS; A. J. KOWALTOWSKI, Aging Cell, (20080800), vol. 7, page 552
	- J. P. BRENNAN et al., Cardiovasc Res, (20061101), vol. 72, page 313
	- Y. H. TSENG; A. M. CYPESS; C. R. KAHN, Nat Rev Drug Discov, (20100600), vol. 9, page 465
	- K. S. PARK et al., Pflugers Arch, (20020100), vol. 443, page 344
	- S. K. JUTHBERG; T. BRISMAR, Cell Mol Neurobiol, (19970800), vol. 17, page 367
	- T. BRISMAR; V. P. COLLINS, J Physiol, (19930100), vol. 460, page 365
	- K. J. BUCKLER; R. D. VAUGHAN-JONES, J Physiol, (19981215), vol. 513, page 819
	- C. HOWARTH; P. GLEESON; D. ATTWELL, J Cereb Blood Flow Metab, (20120700), vol. 32, page 1222
	- G. W. ROGERS et al., PLoS One, (20110000), vol. 6, page e21746
	- P. H. LOU et al., Biochem J, (20071001), vol. 407, page 129
	- E. Y. PLOTNIKOV et al., Biochemistry (Mosc, (20120900), vol. 77, page 1029
	- M. ZHAN; C. BROOKS; F. LIU; L. SUN; Z. DONG, Kidney Int, (20130400), vol. 83, page 568
	- L. LI et al., J Clin Invest, (20121101), vol. 122, page 3931
	- A. BAJWA et al., J Am Soc Nephrol, (20100600), vol. 21, page 955
	- L. LI et al., J Immunol, (20070501), vol. 178, page 5899

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p